Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Archives of Neurology

• Publication date

  2010-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/archneurol.2010.197PMID 20837855PMCID PMC3051403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab add-on therapy for breakthrough relapsing multiple sclerosis

  2010cited by this paper
• Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

  2007cited by this paper
• Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

  2007cited by this paper
• Lack of association between antimyelin antibodies and progression to multiple sclerosis.

  2007cited by this paper
• Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

  2007cited by this paper
• Lack of association between antimyelin antibodies and progression to multiple sclerosis.

  2007cited by this paper
• Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis

  2006cited by this paper
• Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis

  2006cited by this paper
• Antibodies against glycosylated native mog are elevated in patients with multiple sclerosis. Author's reply

  2005cited by this paper
• Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.

  2005cited by this paper
• Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein1

  2005cited by this paper
• Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis.

  2005cited by this paper
• Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

  2005cited by this paper
• Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

  2005cited by this paper
• Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

  2005cited by this paper
• Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects

  2004cited by this paper
• Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination

  2004cited by this paper
• Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.

  2004cited by this paper
• Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis

  2004cited by this paper
• Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients.

  2003cited by this paper
• Cerebrospinal fluid oligoclonal bands in the diagnosis of multiple sclerosis. Isoelectric focusing with IgG immunoblotting compared with high-resolution agarose gel electrophoresis and cerebrospinal fluid IgG index.

  2003cited by this paper
• Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

  2003cited by this paper
• Critical role of antigen‐specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein

  2002cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• B cells and antibodies in CNS demyelinating disease.

  2001cited by this paper
• The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.

  2001cited by this paper
• Immune Responses Against the Myelin/Oligodendrocyte Glycoprotein in Experimental Autoimmune Demyelination

  2001cited by this paper
• T‐ and B‐cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis

  2001cited by this paper
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

  2000cited by this paper
• The role of B cells and autoantibodies in multiple sclerosis

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases.

  1999cited by this paper
• Identification of autoantibodies associated with myelin damage in multiple sclerosis

  1999cited by this paper
• B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide

  1999cited by this paper
• Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis.

  1999cited by this paper
• The Structure and Function of Myelin Oligodendrocyte Glycoprotein

  1999cited by this paper
• Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).

  1999cited by this paper
• Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide.

  1997cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.

  1995cited by this paper
• Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice.

  1994cited by this paper
• Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls.

  1991cited by this paper
• A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications.

  1990cited by this paper
• Demyelination Induced in Aggregating Brain Cell Cultures by a Monoclonal Antibody Against Myelin/Oligodendrocyte Glycoprotein

  1990cited by this paper
• Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein.

  1988cited by this paper
• A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.

  1987cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis.

  1979cited by this paper

• Antibody response against HERV-K polymerase and envelope by patients with multiple sclerosis.

  2026cites this paper
• Anti‐Human Endogenous Retrovirus and Anti‐Myelin Oligodendrocyte Glycoprotein Humoral Response in Cerebrospinal Fluid of Multiple Sclerosis Patients: A Case Control Study

  2025cites this paper
• Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder

  2021cites this paper
• Fulminating Autoimmune Demyelination with Optic Neuropathy in a Case of Pediatric Cerebral Adrenoleukodystrophy: Case Report and Review of the Literature

  2021cites this paper
• Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF

  2021cites this paper
• Multiple Sclerosis

  2020cites this paper
• Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review

  2018cites this paper
• Structural and Metabolic Biomarkers in Multiple Sclerosis

  2018cites this paper
• Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis

  2018cites this paper
• Current Concepts of the Intrathecal Humoral Immune Response and the Diagnostic Significance of the Detection of Oligoclonal Immunoglobulins in Multiple Sclerosis

  2017cites this paper
• Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications

  2017cites this paper
• [Current concepts on intrathecal humoral immune response and diagnostic importance of oligoclonal immunoglobulins in multiple sclerosis].

  2016cites this paper
• Multiple Sclerosis, Mad Cow Disease and Acinetobacter

  2016cites this paper
• MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

  2015cites this paper
• Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases

  2015cites this paper
• The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.

  2015cites this paper
• The Myelin- Acinetobacter- Neurofilament Index in an Attempt to Diagnose Multiple Sclerosis

  2015cites this paper
• Macrophage/Microglia Plasticity in Multiple Sclerosis

  2015cites this paper
• Die Bedeutung von Serum-Antikörpern gegen Myelinproteine vor Erstmanifestation einer Multiplen Sklerose

  2014cites this paper
• Antimyelin antibodies as predictors of disability after clinically isolated syndrome

  2014cites this paper
• Chapter 52 – Multiple Sclerosis

  2014cites this paper
• Evaluation of the humoral response against mycobacterial peptides, homologous to MOG₃₅₋₅₅, in multiple sclerosis patients.

  2014cites this paper
• Protein array–based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis

  2013cites this paper
• [Biomarkers in multiple sclerosis (a review and experimental data)].

  2013cites this paper
• , remitting multiple sclerosis − relapsing Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from

  2013cites this paper
• Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.

  2013cites this paper
• Intrathecal oligoclonal IgG synthesis in multiple sclerosis.

  2013cites this paper
• Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis

  2013cites this paper
• Biomarkers in Multiple Sclerosis: An Up-to-Date Overview

  2013cites this paper
• Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis.

  2012cites this paper
• Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.

  2012cites this paper
• Antigen microarrays identify CNS-produced autoantibodies in RRMS

  2012cites this paper
• B cells set trends: Lessons from multiple sclerosis

  2012cites this paper
• Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression

  2011cites this paper
• Current world literature.

  2011cites this paper
• Trypanosoma cruzi-Induced Central Nervous System Alterations: From the Entry of Inflammatory Cells to Potential Cognitive and Psychiatric Abnormalities

  2010cites this paper
• Neuronal degeneration and macrophage activation in Multiple Sclerosis

  year unknowncites this paper
• Therapeutic Advances in Neurological Disorders Glycoproteins as Targets of Autoantibodies in Cns Inflammation: Mog and More Therapeutic Advances in Neurological Disorders Review

  year unknowncites this paper